HTAi2018: MCDA and EFOR for value based decisions on off-patent pharmaceuticals in developing countries

At the Annual HTAi Meeting 2018 in Vancouver, Canada, we are supporting 2 panel sessions:

1.) Off-Patent Pharmaceuticals in Developing Countries: A Case For Multi-Criteria Decision Analysis

The objective of this panel is to increase the awareness of decision makers in developing countries of an initiative aiming at more rational and value based decision making in the off-patent pharmaceutical sector by using multi criteria decision approach.

Date: June 04, 2018 (Monday) 3:30 PM – 4:45 PM – Presentation ID: ID# PN29

Download here: http://uploads.health-os.com/HTAI2018/Panel29_Presentation_47_MCDA-in-developing-countries.pdf

2.) A Value Based Framework for Off-Patent Pharmaceutical Review (EFOR) in Developing Countries

The objective of this workshop is to present and discuss with the audience a novel approach to support developing countries in making more rational and value based decisions relating to off-patent pharmaceuticals.

EFOR, a simple open-source tool which can be easily adapted to the country’s specific health policy priorities will empower health-care agencies and buyers in emerging markets to make more rational and transparent decisions and improve outcomes for public health.

Date: June 05, 2018 (Tuesday) 9:15 AM – 10:30 AM    –  Presentation ID: ID# PN40

Download here: http://uploads.health-os.com/HTAI2018/Panel40_Presentation_48_Evidence%20Framework%20for%20Off-Patent%20Pharmaceuticals%20Review.pptx.pdf